Latest Information Update: 09 Feb 2001
At a glance
- Originator ALTANA Pharma
- Class Antiulcers
- Mechanism of Action Proton pump inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Peptic ulcer
Most Recent Events
- 09 Feb 2001 Profile reviewed but no significant changes made
- 16 Apr 1997 No-Development-Reported for Peptic ulcer in Germany (Unknown route)